Interpace Biosciences, Inc.
IDXG
$0.9077
-$0.0823-8.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.33% | 13.14% | 21.88% | 35.44% | 9.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.33% | 13.14% | 21.88% | 35.44% | 9.21% |
| Cost of Revenue | -6.61% | 7.19% | 20.66% | 16.13% | 1.07% |
| Gross Profit | -32.41% | 16.78% | 22.35% | 51.51% | 14.21% |
| SG&A Expenses | 10.80% | 6.01% | 21.89% | 16.88% | -8.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.08% | 6.86% | 21.11% | 14.25% | -7.69% |
| Operating Income | -117.78% | 64.18% | 24.27% | 12,006.25% | 216.35% |
| Income Before Tax | -121.19% | 117.16% | 45.44% | 360.69% | 530.33% |
| Income Tax Expenses | -- | 350.00% | -260.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -121.23% | 116.01% | 46.21% | 357.95% | 535.70% |
| Earnings from Discontinued Operations | -44.59% | -2.88% | -78.67% | 4.65% | 66.36% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.26% | 132.63% | 41.63% | 308.47% | 1,292.57% |
| EBIT | -117.78% | 64.18% | 24.27% | 12,006.25% | 216.35% |
| EBITDA | -113.60% | 65.01% | 24.49% | 788.84% | 126.81% |
| EPS Basic | -125.98% | 130.00% | 16.84% | 304.92% | 1,271.67% |
| Normalized Basic EPS | -120.96% | 114.74% | 42.42% | 356.33% | 521.45% |
| EPS Diluted | -126.16% | -65.37% | -89.66% | 304.99% | 1,318.46% |
| Normalized Diluted EPS | -121.08% | -65.61% | -87.37% | 354.62% | 517.99% |
| Average Basic Shares Outstanding | 1.07% | 1.14% | 1.75% | 1.71% | 1.51% |
| Average Diluted Shares Outstanding | 0.50% | 531.93% | 1,045.71% | 2.41% | 1.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |